UNSPSC 51282005: Tyrothricin

This classification denotes A polypeptide antibiotic mixture obtained from Bacillus brevis. It consists of a mixture of three tyrocidines (60%) and several gramicidins (20%), with the molecular formula C65H85N11O13, chemically known as 3-[(3R,6S,9S,12S,15S,17S,20S,22R,25S,28S)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11, 14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23, 26-nonazabicyclo[26.3.0]hentriacontan-17-yl]propanoic acid, but generally known as tyrothricin.

UNSPSC 51282005 Tyrothricin, a Commodity code, covers antibiotic topical and oral pharmaceutical products that state and local health systems and facilities procure through cooperative purchasing agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, recently solicited manufacturers and distributors to supply generic multi-source pharmaceuticals and over-the-counter products to participating state and local government facilities across multiple states including Oregon. The RFP establishes contracts requiring vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with detailed National Drug Code (NDC), SKU, UPC, and manufacturing-location documentation. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place, and carry commercial general liability insurance of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million.

MMCAP represents a multistate and multilocal purchasing vehicle spanning state departments and local government health facilities. The recent RFP (S1070000015802) was posted January 20, 2026, with a response deadline of March 26, 2026; awarded vendors were to be provided to wholesalers by May 15, 2026, with resulting agreements effective July 1, 2026. Evaluation weighted price competitiveness at 75 percent, fixed pricing at 10 percent, and compliance with administrative requirements (format, EDI capability, 3 percent administrative fee agreement) at 15 percent combined. No specific dollar values or set-aside designations are disclosed in the RFP documentation; MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and patient safety. The contract term runs two years for new responders with optional extensions at MMCAP's discretion, or through June 30, 2028 for incumbent vendors.